360 related articles for article (PubMed ID: 28360207)
1.
Grkovski M; Emmas SA; Carlin SD
J Nucl Med; 2017 Oct; 58(10):1567-1573. PubMed ID: 28360207
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic Analysis of Dynamic
Schwartz J; Grkovski M; Rimner A; Schöder H; Zanzonico PB; Carlin SD; Staton KD; Humm JL; Nehmeh SA
J Nucl Med; 2017 Jun; 58(6):911-919. PubMed ID: 28232611
[TBL] [Abstract][Full Text] [Related]
3. Multiparametric Imaging of Tumor Hypoxia and Perfusion with
Grkovski M; Schöder H; Lee NY; Carlin SD; Beattie BJ; Riaz N; Leeman JE; O'Donoghue JA; Humm JL
J Nucl Med; 2017 Jul; 58(7):1072-1080. PubMed ID: 28183993
[TBL] [Abstract][Full Text] [Related]
4. Comparison of three
Dos Santos SN; Wuest M; Jans HS; Woodfield J; Nario AP; Krys D; Dufour J; Glubrecht D; Bergman C; Bernardes ES; Wuest F
Nucl Med Biol; 2023; 124-125():108383. PubMed ID: 37651917
[TBL] [Abstract][Full Text] [Related]
5. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O.
Bruehlmeier M; Roelcke U; Schubiger PA; Ametamey SM
J Nucl Med; 2004 Nov; 45(11):1851-9. PubMed ID: 15534054
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of 18F-Fluoromisonidazole Kinetic Modeling in Head and Neck Cancer Using Shortened Acquisition Times.
Grkovski M; Schwartz J; Gönen M; Schöder H; Lee NY; Carlin SD; Zanzonico PB; Humm JL; Nehmeh SA
J Nucl Med; 2016 Mar; 57(3):334-41. PubMed ID: 26609178
[TBL] [Abstract][Full Text] [Related]
7. 18F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors.
Oehler C; O'Donoghue JA; Russell J; Zanzonico P; Lorenzen S; Ling CC; Carlin S
J Nucl Med; 2011 Mar; 52(3):437-44. PubMed ID: 21321262
[TBL] [Abstract][Full Text] [Related]
8. Monitoring early response to chemoradiotherapy with
Grkovski M; Lee NY; Schöder H; Carlin SD; Beattie BJ; Riaz N; Leeman JE; O'Donoghue JA; Humm JL
Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1682-1691. PubMed ID: 28540417
[TBL] [Abstract][Full Text] [Related]
9. Quantification of Tumor Hypoxic Fractions Using Positron Emission Tomography with [
Kelada OJ; Rockwell S; Zheng MQ; Huang Y; Liu Y; Booth CJ; Decker RH; Oelfke U; Carson RE; Carlson DJ
Mol Imaging Biol; 2017 Dec; 19(6):893-902. PubMed ID: 28409339
[TBL] [Abstract][Full Text] [Related]
10. Complementary information from magnetic resonance imaging and (18)F-fluoromisonidazole positron emission tomography in the assessment of the response to an antiangiogenic treatment in a rat brain tumor model.
Valable S; Petit E; Roussel S; Marteau L; Toutain J; Divoux D; Sobrio F; Delamare J; Barré L; Bernaudin M
Nucl Med Biol; 2011 Aug; 38(6):781-93. PubMed ID: 21843775
[TBL] [Abstract][Full Text] [Related]
11. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.
O'Donoghue JA; Zanzonico P; Pugachev A; Wen B; Smith-Jones P; Cai S; Burnazi E; Finn RD; Burgman P; Ruan S; Lewis JS; Welch MJ; Ling CC; Humm JL
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1493-502. PubMed ID: 15817355
[TBL] [Abstract][Full Text] [Related]
12.
McGowan DR; Macpherson RE; Hackett SL; Liu D; Gleeson FV; McKenna WG; Higgins GS; Fenwick JD
Med Phys; 2017 Sep; 44(9):4665-4676. PubMed ID: 28644546
[TBL] [Abstract][Full Text] [Related]
13. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
Okamoto S; Shiga T; Yasuda K; Ito YM; Magota K; Kasai K; Kuge Y; Shirato H; Tamaki N
J Nucl Med; 2013 Feb; 54(2):201-7. PubMed ID: 23321456
[TBL] [Abstract][Full Text] [Related]
14. Comparison of DCE-MRI kinetic parameters and FMISO-PET uptake parameters in head and neck cancer patients.
Simoncic U; Leibfarth S; Welz S; Schwenzer N; Schmidt H; Reischl G; Pfannenberg C; Fougère C; Nikolaou K; Zips D; Thorwarth D
Med Phys; 2017 Jun; 44(6):2358-2368. PubMed ID: 28317128
[TBL] [Abstract][Full Text] [Related]
15. Comparative evaluation of [
Nakata N; Kiriu M; Okumura Y; Zhao S; Nishijima KI; Shiga T; Tamaki N; Kuge Y; Matsumoto H
Nucl Med Biol; 2019 Mar; 70():39-45. PubMed ID: 30836255
[TBL] [Abstract][Full Text] [Related]
16. Quantitative Analysis of [
Shi K; Bayer C; Astner ST; Gaertner FC; Vaupel P; Schwaiger M; Huang SC; Ziegler SI
Mol Imaging Biol; 2017 Feb; 19(1):120-129. PubMed ID: 27379986
[TBL] [Abstract][Full Text] [Related]
17. Response of HT29 colorectal xenograft model to cediranib assessed with 18 F-fluoromisonidazole positron emission tomography, dynamic contrast-enhanced and diffusion-weighted MRI.
Bokacheva L; Kotedia K; Reese M; Ricketts SA; Halliday J; Le CH; Koutcher JA; Carlin S
NMR Biomed; 2013 Feb; 26(2):151-63. PubMed ID: 22777834
[TBL] [Abstract][Full Text] [Related]
18. Correlation of Tumor Hypoxia Metrics Derived from
Scarpelli ML; Healey DR; Fuentes A; Kodibagkar VD; Quarles CC
Tomography; 2020 Dec; 6(4):379-388. PubMed ID: 33364428
[No Abstract] [Full Text] [Related]
19. Radiosensitizing effect of irisquinone on glioma through the downregulation of HIF-1α evaluated by 18F-FDG and 18F-FMISO PET/CT.
Wang H; Zhang Y; Yu W; Zhao X; Xue Y; Xu H
Nucl Med Commun; 2016 Jul; 37(7):705-14. PubMed ID: 26963468
[TBL] [Abstract][Full Text] [Related]
20.
Yu W; Qiao F; Su X; Zhang D; Wang H; Jiang J; Xu H
Biomed Pharmacother; 2019 Nov; 119():109454. PubMed ID: 31526971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
